BioNTech料9月将有婴儿接种疫苗临床测试数据
德国《明镜》周刊引述BioNTech(BNTX.US)行政总裁Ugur Sahin称,公司与辉瑞(PFE.US)就新冠疫苗对小至仅六个月大婴儿的临床测试料9月将有结果。Sahin称,7月将获得5至12岁小童的结果,9月将有更年幼小孩的结果。他补充需要四至六星期评估数据。
Sahin称,倘一切顺利,当数据完成评估後,将在不同国家就向所有年龄类别小孩接种疫苗提交许可申请。BioNTech及辉瑞促请美国本月容许向12至15岁青年紧急批准采用旗下疫苗。
报道引述Sahin称,公司在向欧洲监管机构寻求对12岁或以上青年接种疫苗许可一事上已届递交申请前最後阶段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.